David Riseberg

1.2k total citations
8 papers, 166 citations indexed

About

David Riseberg is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, David Riseberg has authored 8 papers receiving a total of 166 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 4 papers in Cancer Research and 3 papers in Pathology and Forensic Medicine. Recurrent topics in David Riseberg's work include Breast Cancer Treatment Studies (3 papers), Cancer Treatment and Pharmacology (3 papers) and Advanced Breast Cancer Therapies (2 papers). David Riseberg is often cited by papers focused on Breast Cancer Treatment Studies (3 papers), Cancer Treatment and Pharmacology (3 papers) and Advanced Breast Cancer Therapies (2 papers). David Riseberg collaborates with scholars based in United States, Spain and Portugal. David Riseberg's co-authors include David N. Danforth, Marianne Noone, Mark D. Pegram, Giuseppe Curigliano, Sam Pyo Hong, William J. Gradishar, Seock‐Ah Im, Hope S. Rugo, Michelino De Laurentiis and Shakeela Bahadur and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

David Riseberg

8 papers receiving 165 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Riseberg United States	6	103	58	45	43	28	8	166
Jason Mouabbi United States	7	113 1.1×	100 1.7×	51 1.1×	64 1.5×	23 0.8×	41	205
Tetsuhiro Yoshinami Japan	6	116 1.1×	50 0.9×	18 0.4×	53 1.2×	22 0.8×	48	174
Arielle J. Medford United States	8	139 1.3×	98 1.7×	38 0.8×	88 2.0×	23 0.8×	44	247
Loïc Bergougnoux France	6	221 2.1×	28 0.5×	38 0.8×	68 1.6×	33 1.2×	6	261
T Anderson United States	7	156 1.5×	42 0.7×	36 0.8×	29 0.7×	124 4.4×	8	243
Özlem Nuray Sever Türkiye	9	204 2.0×	92 1.6×	61 1.4×	51 1.2×	9 0.3×	38	278
Federica Predolini United States	9	148 1.4×	35 0.6×	47 1.0×	50 1.2×	46 1.6×	12	275
Walter Lindemann Germany	5	126 1.2×	71 1.2×	11 0.2×	45 1.0×	64 2.3×	5	189
Casey Liveringhouse United States	8	99 1.0×	85 1.5×	35 0.8×	85 2.0×	48 1.7×	27	194
Robin Meng United States	5	118 1.1×	20 0.3×	30 0.7×	30 0.7×	29 1.0×	10	234

Countries citing papers authored by David Riseberg

Since Specialization

Citations

This map shows the geographic impact of David Riseberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Riseberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Riseberg more than expected).

Fields of papers citing papers by David Riseberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Riseberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Riseberg. The network helps show where David Riseberg may publish in the future.

Co-authorship network of co-authors of David Riseberg

This figure shows the co-authorship network connecting the top 25 collaborators of David Riseberg. A scholar is included among the top collaborators of David Riseberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Riseberg. David Riseberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Im, Seock‐Ah, Fátima Cardoso, Javier Cortés, et al.. (2020). SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) + Ctx versus trastuzumab (T) + Ctx in patients (pts) with pretreated HER2+ metastatic (met) breast cancer (MBC).. Journal of Clinical Oncology. 38(15_suppl). 1040–1040. 5 indexed citations

Rugo, Hope S., Seock‐Ah Im, Santiago Escrivá-de-Romaní, et al.. (2019). SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).. Journal of Clinical Oncology. 37(15_suppl). 1000–1000. 62 indexed citations

Gallicchio, Lisa, et al.. (2016). Cardiovascular Health among Black and White Breast Cancer Patients Initiating Aromatase Inhibitor Therapy. The Breast Journal. 23(2). 206–209. 13 indexed citations

Riseberg, David. (2015). Treating Elderly Patients with Hormone Receptor–Positive Advanced Breast Cancer. Clinical Medicine Insights Oncology. 9. 65–73. 13 indexed citations

Zujewski, Jo Anne, Jennifer Eng‐Wong, Joyce O’Shaughnessy, et al.. (2003). A Pilot Study of Dose Intense Doxorubicin and Cyclophosphamide Followed by Infusional Paclitaxel in High-Risk Primary Breast Cancer. Breast Cancer Research and Treatment. 81(1). 41–51. 5 indexed citations

Danforth, David N., JoAnne Zujewski, Joyce O’Shaughnessy, et al.. (1998). Selection of local therapy after neoadjuvant chemotherapy in patients with stage IIIA,B breast cancer. Annals of Surgical Oncology. 5(2). 150–158. 33 indexed citations

Schwartz, Gretchen N., Frances T. Hakim, J. Zujewski, et al.. (1996). Early suppressive effects of chemotherapy and cytokine treatment on committed versus primitive haemopoietic progenitors in patient bone marrow. British Journal of Haematology. 92(3). 537–547. 9 indexed citations

O’Shaughnessy, J., Anthony W. Tolcher, David Riseberg, et al.. (1996). Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients with advanced breast cancer. Blood. 87(6). 2205–2211. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact